R-Biopharm announces test to detect monkeypox virus

1684311130 R Biopharm announces test to detect monkeypox virus | mifuturonorcal

Test for research purposes coming soon

Darmstadt, Germany, June 1, 2022 – R-Biopharm AG, a leading globally operating biotechnology company headquartered in Germany, will soon launch a test for the detection of monkeypox virus. The real-time PCR test, developed for research purposes (RUO), will help track and control the epidemiological spread of the virus.

R-Biopharm announces test to detect monkeypox virus

The product should be available in approximately two to three weeks under the name RIDA®GENE Monkeypox Virus RUO (part number PG4915RUO). Like the test for the detection of the SARS-CoV-2 virus, which was first launched by a German company for research purposes in February 2020 and was officially approved for the diagnosis of SARS-CoV-2 in the autumn of 2020 with the CE mark, the real-time PCR test for the detection of monkeypox virus will also be usable on all common real-time PCR instruments. The uniform design of RIDA®GENE also allows users to perform this test together with other RIDA®GENE products.

« R-Biopharm cares about the common good, » says Dr. Andreas Simons, Head of Product Management Clinical Diagnostics at R-Biopharm. « That’s why we immediately set to work designing the primers and probes needed for reliable detection when the first report came in from the Robert Koch Institute of a monkeypox case that was unrelated to a visit to Africa. »

About R-Biopharm
R-Biopharm AG, headquartered in Darmstadt, is one of the leading biotechnology companies in Germany. He considers himself a pioneer in health and quality of life. The company’s aspiration is to provide the greatest possible precision, safety, clarity and certainty with excellent products and solutions – in prevention, therapy and healing. R-Biopharm research and development has developed agile processes to face new challenges to accompany a constantly growing world population into a new era of health with sustainable solutions.

As an internationally recognized leader, R-Biopharm stands for the development of excellent technologies, products and solutions in the fields of clinical diagnostics, nutrition care and food and feed analysis. R-Biopharm is the global market leader for test systems in the field of allergen analysis. The biotech company is known for its products of great importance to human health. To this end, it combines development, production and sales under one roof and is successfully represented in more than 120 countries worldwide, via 28 subsidiaries and 120 distributors. Founded in 1988, the family-owned company employs a total of around 1,300 people worldwide (690 at the headquarters in Darmstadt) and has been awarded the « Sustainability Award » several times for sustainable and profitable growth. R-Biopharm cultivates a value-oriented corporate culture and management and is family-owned in the second generation. The chairman of the board of directors is Christian Dreher.

Image: http://www.apimages.com

Press contact:
Simone Feler
Responsible for corporate brand communication
https://r-biopharm.com/
https://r-biopharm.com/news-press/download-gallery/

R-Biopharm AG
At the new mountain road 17
64297 Darmstadt, Germany
Phone: +49 61 51 – 81 02-538
Mobile: +49 160 – 55 273 60
Fax: +49 61 51 – 81 02-40
Email: s.feiler@r-biopharm.de